Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries LAWSUITS FILED AGAINST SAM, EAR and SBTX - Jakubowitz Law Pursues Shareholders Claims By: Jakubowitz Law via AccessWire November 12, 2021 at 12:00 PM EST NEW YORK, NY / ACCESSWIRE / November 12, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.The Boston Beer Company, Inc. (NYSE:SAM)CONTACT JAKUBOWITZ ABOUT SAM:https://claimyourloss.com/securities/the-boston-beer-company-inc-loss-submission-form/?id=21135&from=1Class Period : April 22, 2021 - September 8, 2021Lead Plaintiff Deadline : November 15, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Boston Beer's hard seltzer sales were decelerating; (2) as a result, Boston Beer was reasonably likely to incur inventory write-offs; (3) the Company was reasonably likely to incur shortfall fees payable to third party brewers; (4) as a result of the foregoing, Boston Beer's financial results would be adversely impacted; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.Eargo, Inc. (NASDAQ:EAR)CONTACT JAKUBOWITZ ABOUT EAR:https://claimyourloss.com/securities/eargo-inc-loss-submission-form/?id=21135&from=1This lawsuit is on behalf of all persons or entities that purchased or otherwise acquired: (a) Eargo shares in or traceable to the Company's initial public offering of common stock conducted on or around October 15, 2020 (the "Offering"); and/or (b) shares of Eargo common stock between October 15, 2020 and September 22, 2021, inclusive.Lead Plaintiff Deadline : December 6, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Eargo had improperly sought reimbursements from certain third-party payors; (2) the foregoing was reasonably likely to lead to regulatory scrutiny; (3) as a result and because the reimbursements at issue involved the Company's largest third-party payor, Eargo's financial results would be adversely impacted; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.Silverback Therapeutics, Inc. (NASDAQ:SBTX)CONTACT JAKUBOWITZ ABOUT SBTX:https://claimyourloss.com/securities/silverback-therapeutics-inc-loss-submission-form/?id=21135&from=1This lawsuit is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Silverback common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about December 3, 2020 and/or (b) Silverback securities between December 3, 2020 and September 10, 2021, both dates inclusive.Lead Plaintiff Deadline : January 4, 2022The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Silverback's lead product candidate SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers, was less effective than the Company had represented to investors; (ii) accordingly, the Company had overstated SBT6050's commercial and/or clinical prospects; and (iii) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:JAKUBOWITZ LAW1140 Avenue of the Americas9th FloorNew York, New York 10036T: (212) 867-4490F: (212) 537-5887SOURCE: Jakubowitz Law View source version on accesswire.com: https://www.accesswire.com/672629/LAWSUITS-FILED-AGAINST-SAM-EAR-and-SBTX--Jakubowitz-Law-Pursues-Shareholders-Claims Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
LAWSUITS FILED AGAINST SAM, EAR and SBTX - Jakubowitz Law Pursues Shareholders Claims By: Jakubowitz Law via AccessWire November 12, 2021 at 12:00 PM EST NEW YORK, NY / ACCESSWIRE / November 12, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.The Boston Beer Company, Inc. (NYSE:SAM)CONTACT JAKUBOWITZ ABOUT SAM:https://claimyourloss.com/securities/the-boston-beer-company-inc-loss-submission-form/?id=21135&from=1Class Period : April 22, 2021 - September 8, 2021Lead Plaintiff Deadline : November 15, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Boston Beer's hard seltzer sales were decelerating; (2) as a result, Boston Beer was reasonably likely to incur inventory write-offs; (3) the Company was reasonably likely to incur shortfall fees payable to third party brewers; (4) as a result of the foregoing, Boston Beer's financial results would be adversely impacted; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.Eargo, Inc. (NASDAQ:EAR)CONTACT JAKUBOWITZ ABOUT EAR:https://claimyourloss.com/securities/eargo-inc-loss-submission-form/?id=21135&from=1This lawsuit is on behalf of all persons or entities that purchased or otherwise acquired: (a) Eargo shares in or traceable to the Company's initial public offering of common stock conducted on or around October 15, 2020 (the "Offering"); and/or (b) shares of Eargo common stock between October 15, 2020 and September 22, 2021, inclusive.Lead Plaintiff Deadline : December 6, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Eargo had improperly sought reimbursements from certain third-party payors; (2) the foregoing was reasonably likely to lead to regulatory scrutiny; (3) as a result and because the reimbursements at issue involved the Company's largest third-party payor, Eargo's financial results would be adversely impacted; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.Silverback Therapeutics, Inc. (NASDAQ:SBTX)CONTACT JAKUBOWITZ ABOUT SBTX:https://claimyourloss.com/securities/silverback-therapeutics-inc-loss-submission-form/?id=21135&from=1This lawsuit is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Silverback common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about December 3, 2020 and/or (b) Silverback securities between December 3, 2020 and September 10, 2021, both dates inclusive.Lead Plaintiff Deadline : January 4, 2022The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Silverback's lead product candidate SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers, was less effective than the Company had represented to investors; (ii) accordingly, the Company had overstated SBT6050's commercial and/or clinical prospects; and (iii) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:JAKUBOWITZ LAW1140 Avenue of the Americas9th FloorNew York, New York 10036T: (212) 867-4490F: (212) 537-5887SOURCE: Jakubowitz Law View source version on accesswire.com: https://www.accesswire.com/672629/LAWSUITS-FILED-AGAINST-SAM-EAR-and-SBTX--Jakubowitz-Law-Pursues-Shareholders-Claims